Octreotide for the treatment of chylothorax in neonates
- 8 September 2010
- journal article
- review article
- Published by Wiley in Emergencias
- No. 9,p. CD006388
- https://doi.org/10.1002/14651858.cd006388.pub2
Abstract
Background Routine care for chylothorax in neonate includes either conservative or surgical approaches. Octreotide, a somatostatin analogue, has been used for the management of patients with refractory chylothorax not responding to conservative management. Objectives To assess the efficacy and safety of octreotide in the treatment of chylothorax in neonates. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE and EMBASE (to March 7, 2010). We assessed the reference lists of identified trials and abstracts from the annual meetings of the Pediatric Academic Societies published in Pediatric Research (2002 to 2009) without language restrictions. Selection criteria We planned to include randomised or quasi‐randomised controlled trials of octreotide in the treatment of congenital or acquired chylothorax in term or preterm neonates, with any dose, duration or route of administration. Data collection and analysis Data on primary (amount of fluid drainage, respiratory support, mortality) and secondary outcomes (side effects) were planned to be collected and analysed using mean difference, relative risk and risk difference with 95% confidence intervals. Main results No randomised controlled trials were identified. Nineteen case reports of 20 neonates with chylothorax in whom octreotide was used either subcutaneously or intravenously were identified. Fourteen case reports described successful use (resolution of chylothorax), four reported failure (no resolution) and one reported equivocal results following use of octreotide. The timing of initiation, dose, duration and frequency of doses varied markedly. Gastrointestinal intolerance and clinical presentations suggestive of necrotizing enterocolitis and transient hypothyroidism were reported as side effects. Authors' conclusions No practice recommendation can be made based on the evidence identified in this review. A prospective registry of chylothorax patients and a subsequent multicenter randomised controlled trial are needed to assess the safety and efficacy of octreotide in the treatment of chylothorax in neonates.Keywords
This publication has 30 references indexed in Scilit:
- Idiopathic congenital chylothorax presented with severe hydrops and treated with octreotide in term newbornThe Journal of Maternal-Fetal & Neonatal Medicine, 2009
- The use of octreotide to treat congenital chylothoraxJournal of Pediatric Surgery, 2006
- Spontaneous neonatal chylothorax treated with octreotideJournal of Paediatrics and Child Health, 2006
- Nonimmune Hydrops Fetalis Due to Generalized Lymphatic Dysplasia in an Infant with Robertsonian Trisomy 21American Journal of Perinatology, 2005
- Postoperative Chylous Ascites in a Neonate Treated Successfully with Octreotide: Bile Sludge and CholestasisAmerican Journal of Perinatology, 2005
- Somatostatin treatment of spontaneous chylothorax in an extremely low birth weight infantEuropean Journal of Pediatrics, 2004
- Octreotide in the treatment of congenital chylothoraxJournal of Paediatrics and Child Health, 2004
- Somatostatin analog (octreotide) in management of neonatal postoperative chylothorax: Is it safe?Pediatric Critical Care Medicine, 2004
- Management of newborn lymphangiectasia and chylothorax after cardiac surgery with octreotide infusionThe Annals of Thoracic Surgery, 2004
- Persistent hyperinsulinemic hypoglycemia of infancy: Long-term octreotide treatment without pancreatectomyThe Journal of Pediatrics, 1993